StageUnattributed VC | Alive
InSphero provides pharmaceutical and biotechnology services. It focuses on industrial-grade, three-dimensional (3D)-cell-based assay solutions, and organ-on-a-chip technology for pharmaceutical drug discovery and safety testing. The company specializes in liver toxicology, metabolic diseases, diabetes, and Immuno oncology. InSphero was founded in 2009 and is based in Schlieren, Switzerland.
Missing: InSphero's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
ESPs containing InSphero
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
The organ-on-a-chip market is an innovative field of research focused on creating micro-scale models of human organs using microfluidic technology. This market offers a range of solutions that allow for the simulation of complex biological processes that occur within organs, including drug metabolism, toxicity testing, and disease modeling. By using organ-on-a-chip models, researchers can reduce t…
InSphero named as Leader among 15 other companies, including Emulate, CN Bio Innovations, and Quris AI.
Missing: InSphero's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing InSphero
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
InSphero is included in 6 Expert Collections, including Cancer.
Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.
Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).
Drug Discovery Tech Market Map
This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
InSphero has filed 10 patents.
The 3 most popular patent topics include:
- Fluid dynamics
- Cell biology
Safety equipment, Postal system, Fluid dynamics, Bearings (mechanical), Hydraulics
Safety equipment, Postal system, Fluid dynamics, Bearings (mechanical), Hydraulics
Latest InSphero News
May 13, 2023
Organisation Scailyte announces Jan Lichtenberg, CEO at InSphero, as a member of the Board of Directors Scailyte, a biomarker discovery company leveraging single-cell omics and artificial intelligence, is proud to announce the appointment of Jan Lichtenberg to its Board of Directors. Jan Lichtenberg, PhD, is Co-Founder and CEO of Swiss- and US-based InSphero Inc., the world-leading biotech specialising in 3D cell-culture technologies for discovery and safety. With over 20 years of experience in the life sciences and expertise in engineering and laboratory automation, Jan brings a wealth of knowledge and leadership to Scailytes board. Jan earned his PhD in Microtechnology and Microfluidics from the University of Neuchâtel, Switzerland, and has a track record of successfully leading and growing biotech companies. His experience includes VP R&D and Product Management positions at Hocoma AG (medical robotics) and Uwatec (microelectronics). Jans comment: I am excited to join the Board of Scailyte, which has impressed me with their unique technology platform and deep understanding of the challenges of analyzing complex biological data. The combination of single-cell genomics and data analysis has the potential to revolutionize our understanding of biology and disease, and to enable the development of new diagnostics and therapies that are tailored to the individual characteristics of patients. Helping to achieve this is a great honor. Peter Nestorov, Co-Founder and CEO of Scailyte, is similarly excited: Jan is a passionate and very experienced entrepreneur who brings in a lot of experience related to developing and commercializing life science products. In particular, Jans experience in establishing a successful business model embedded in drug discovery is highly relevant to Scailyte and can help us to achieve commercial success and advance Scailyte to becoming a global biomarker discovery leader. Jan will be taking the place of Jean-Pierre Rosat, General Partner at 4FOX ventures. Jean-Pierre has provided valuable strategic insights and guidance to the company, and brought in his network to leading global experts. Jean-Pierre will continue to support the company as a Board Observer. With Lichtenbergs appointment, Scailyte has further strengthened its Board of Directors with an experienced industry leader who will play an important role in shaping the companys future. The company remains committed to advancing the field of precision medicine with single-cell technologies, artificial intelligence, and multi-omics analysis. About Scailyte Scailyte is an ETH Zürich spin-off with a proprietary artificial intelligence platform for the discovery of complex disease patterns from single-cell data. Our solution ScaiVision® provides unprecedented insight into the disease and patients biology and enables the discovery of new clinically-relevant biomarker signatures, with a focus on oncology and immunology. Scailytes proprietary data analysis platform ScaiVision® associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc.) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, and toxicity response to identify ultra-sensitive biomarker signatures and cell functionality states. The performance and clinically relevant applications of Scailytes platform ScaiVision® have been demonstrated in various projects in oncology and immunology. Additionally, Scailyte leverages a broad network of top clinicians to identify clinical indications with high unmet clinical needs and collaborates with global pharmaceutical and biotech companies to translate novel biomarkers into ultra-sensitive companion diagnostics (CDx) or IVD assays. For more information, visit www.scailyte.com and connect on social media @LinkedIn and @Twitter. ScailyteTM and ScaiVisionTM are registered trademarks proprietary to Scailyte AG.
InSphero Frequently Asked Questions (FAQ)
When was InSphero founded?
InSphero was founded in 2009.
Where is InSphero's headquarters?
InSphero's headquarters is located at Wagistrasse 27A, Schlieren.
What is InSphero's latest funding round?
InSphero's latest funding round is Unattributed VC.
How much did InSphero raise?
InSphero raised a total of $38.83M.
Who are the investors of InSphero?
Investors of InSphero include ZEISS Ventures, European Commission, Euronext, Eurostars Programme, Cellphmed and 10 more.
Who are InSphero's competitors?
Competitors of InSphero include MBD and 1 more.
Compare InSphero to Competitors
Emulate develops an automated bio-emulation platform. It offers a brain chip, a colon-intestine chip, a duodenum-intestine chip, a kidney chip, a liver chip, and more. The company was founded in 2014 and is based in Boston, Massachusetts.
Stemnovate delivers drug-screening and safety-testing platforms. Its user-friendly, flexible platforms overcome the limitations of mammalian cell-lines and in-vivo models commonly used in drug-discovery.
TissUse biotechnology company. It develops a multi-organ-chip platform providing preclinical insight on the systemic level using human tissue. It enables a technology platform consisting of a miniaturized construct that simulates the activity of multiple human organs in their true physiological context. It was founded in 2010 and is based in Berlin, Germany.
MIMETAS develops organ-on-a-chip technology for testing of new medicines. Its microfluidic technology enables testing of drug compounds in high-throughput on miniaturized organ models. These models have better predictivity compared to laboratory animals and conventional cell culture models. The MIMETAS OrganoPlate platform supports 3D cell culture under continuous perfusion, membrane-free co-culture and boundary- and gradient formation. MIMETAS develops and validates customised disease, toxicology and transport models and ultimately will make its technology available for personalized therapy selection.
AxoSim facilitates preclinical prediction of neurological safety and efficacy early in the drug development pipeline. Employing microengineering techniques and biomaterials, the company has developed a 3D cell-based model which mimics living tissue in both form and function. By providing an alternative to exploratory animal testing, pharmaceutical companies will have access to high content data faster and earlier than currently possible.
React4life operates as a biotechnology company. The company's technology recreates physiological environments and allows the cultivation of three-dimensional (3D) tissues of clinically relevant dimensions on which to perform in vitro testing. The project aims to improve the effectiveness of laboratory tests, experiment with therapeutic approaches, and reduce animal testing. The company was founded in 2016 and is based in Genova, Italy.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.